May 24, 2007

Fighting Fibroids: St. Louis Area Gynecologists Now Treat Severely Symptomatic Tumors Without Surgery

ST. LOUIS, May 24 /PRNewswire/ -- One out of every three hysterectomies performed are due to benign tumors (uterine fibroids). Over 25 percent of women in the United States have clinically symptomatic uterine fibroids and as many as 77 percent of all women could have uterine fibroids and many do not even know it.

There is good news for St. Louis women suffering from the painful, embarrassing side effects of uterine fibroids. Local area gynecologists now have access to a revolutionary non-invasive outpatient procedure. The ExAblate procedure combines magnetic resonance imaging and focused ultrasound to kill these tumors. ExAblate of St. Louis, the only facility in Missouri and five surrounding states to offer this incisionless procedure, is now open at Chesterfield Valley Medical Building II, 17300 North Outer 40 Road, Suite 101 in Chesterfield.

"The patients we have treated have returned to normal activities in one to two days. Other surgical treatments for fibroids are invasive and can require several days of hospital stay and up to six weeks of recovery time. The ExAblate technology combines magnetic resonance imaging and focused ultrasound, which enables us to not only see the fibroid and surrounding organs in 3D, but to kill the targeted tumors inside the body without the need for traditional surgical incisions," said Dr. Gordon Goldman, medical director for ExAblate of St. Louis.

The ExAblate treatment offers women with symptomatic uterine fibroids the only non-invasive alternative to surgical treatment options such as hysterectomy, myomectomy, and uterine artery embolization (UAE). Hysterectomy, the full removal of the uterus, can lead to complications associated with major surgery and can send the patient into early menopause. The procedure requires two to five days of hospitalization and six to eight weeks of recovery. Myomectomy, the surgical removal of the fibroid, and UAE both may require hospitalization and lengthy recovery time. With ExAblate, the patient goes home the same day of the procedure and can return to normal activities within two days.

Over 3,000 patients worldwide have already benefited from The ExAblate treatment which is the only U.S. Food and Drug Administration (FDA) - approved system to use the breakthrough MR-guided Focused Ultrasound (MRgFUS) technology that combines MRI -- to visualize tissues in the body, plan the treatment and monitor, in real time, treatment progress -- and high intensity focused ultrasound to thermally ablate tissue. MR thermal feedback, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure the targeted tumor is fully treated and surrounding, normal tissue is spared. ExAblate received FDA approval for the treatment of symptomatic uterine fibroids in October 2004.

ExAblate of St. Louis is a joint venture between local physicians and Deployed Medical Solutions Inc., a Houston, Texas based company dedicated to providing patients and gynecologists access to this revolutionary new technology. Deployed Medical Solutions owns and operates six facilities across the country.

"We are pleased that we will be able to offer our gynecologists and the women of Missouri access to this new, non-invasive treatment for a condition that has previously only been treated with invasive surgery," said Charles Cohen, president and chief executive officer of Deployed Medical Solutions, Inc.

For more information on the ExAblate procedure please visit us on the web at and or call toll free: 877-ExAblate (877-392-2528) or (636)-537-3671.

About Uterine Fibroids

Uterine fibroids are benign growths in the uterus that affect approximately 13 million women of child-bearing age in the U.S. and can cause heavy bleeding that leads to anemia, bloating, abdominal pain and other symptoms. Each year approximately 200,000 women have hysterectomies to treat uterine fibroids. Unlike hysterectomy, myomectomy and UAE, ExAblate is completely non-invasive, using MR guided focused ultrasound to thermally ablate (destroy) growths in the uterus. For women this means no hospital stay and only 1-2 days of recovery as opposed to one week (UAE); two weeks (myomectomy); or six weeks (hysterectomy) usually associated with treatment of this condition.

About ExAblate of St. Louis

ExAblate of St. Louis provides access to the ExAblate technology to gynecologists who understand their patients' need for a non-invasive yet effective option for treating uterine fibroids. ExAblate of St. Louis is the first and only entity in Missouri that provides this innovative procedure and is the only facility in the Midwest that provides training for gynecologists to treat their own patients with this procedure. ExAblate of St. Louis is a dedicated provider of the ExAblate procedure using MR guided Focused Ultrasound Surgery that significantly improves the patient's quality of life.

ExAblate of St. Louis

CONTACT: Margot Harkinson, +1-281-820-7900,[email protected], for ExAblate of St. Louis

Web site: